Neuromuscular diseases are characterized by progressive muscle degeneration and muscle weakness resulting in functional disabilities. While each of these diseases is individually rare, they are common as a group, and a large majority lacks effective treatment with fully market approved drugs. Magnetic resonance imaging and spectroscopy techniques (MRI and MRS) are showing increasing promise as an outcome measure in clinical trials for these diseases. In 2013, the European Union funded the COST (co-operation in science and technology) action BM1304 called MYO-MRI (www.myo-mri.eu), with the overall aim to advance novel MRI and MRS techniques for both diagnosis and quantitative monitoring of neuromuscular diseases through sharing of expertise and data, joint development of protocols, opportunities for young researchers and creation of an online atlas of muscle MRI and MRS. In this report, the topics that were discussed in the framework of working group 3, which had the objective to: Explore new contrasts, new targets and new imaging techniques for NMD are described. The report is written by the scientists who attended the meetings and presented their data. An overview is given on the different contrasts that MRI can generate and their application, clinical needs and desired readouts, and emerging methods.
Diffusion MRI (dMRI) has become an invaluable tool to assess the microstructural organization of brain tissue. Depending on the specific acquisition settings, the dMRI signal encodes specific properties of the underlying diffusion process. In the last two decades, several signal representations have been proposed to fit the dMRI signal and decode such properties. Most methods, however, are tested and developed on a limited amount of data, and their applicability to other acquisition schemes remains unknown. With this work, we aimed to shed light on the generalizability of existing dMRI signal representations to different diffusion encoding parameters and brain tissue types. To this end, we organized a community challenge - named MEMENTO, making available the same datasets for fair comparisons across algorithms and techniques. We considered two state-of-the-art diffusion datasets, including single-diffusion-encoding (SDE) spin-echo data from a human brain with over 3820 unique diffusion weightings (the MASSIVE dataset), and double (oscillating) diffusion encoding data (DDE/DODE) of a mouse brain including over 2520 unique data points. A subset of the data sampled in 5 different voxels was openly distributed, and the challenge participants were asked to predict the remaining part of the data. After one year, eight participant teams submitted a total of 80 signal fits. For each submission, we evaluated the mean squared error, the variance of the prediction error and the Bayesian information criteria. The received submissions predicted either multi-shell SDE data (37%) or DODE data (22%), followed by cartesian SDE data (19%) and DDE (18%). Most submissions predicted the signals measured with SDE remarkably well, with the exception of low and very strong diffusion weightings. The prediction of DDE and DODE data seemed more challenging, likely because none of the submissions explicitly accounted for diffusion time and frequency. Next to the choice of the model, decisions on fit procedure and hyperparameters play a major role in the prediction performance, highlighting the importance of optimizing and reporting such choices. This work is a community effort to highlight strength and limitations of the field at representing dMRI acquired with trending encoding schemes, gaining insights into how different models generalize to different tissue types and fiber configurations over a large range of diffusion encodings. ; Funding Agencies|European Research Council (ERC) under the European UnionEuropean Research Council (ERC) [694665]; French government, through the 3IA Cote DAzur Investments in the Future project [ANR-19-P3IA-0002]; EPSRCUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/N018702/1, MR/T020296/1, ISLRA-2009]; European Space AgencyEuropean Space AgencyEuropean Commission; Belgian Science Policy Office-ProdexBelgian Federal Science Policy Office; Research Foundation Flanders (FWO Vlaanderen)FWO [12M3119N, G0D7216N]; Wellcome Trust Investigator AwardWellcome Trust [096646/Z/11/Z]; Wellcome Trust Strategic AwardWellcome Trust [104943/Z/14/Z]; Polish National Agency for Academic ExchangePolish National Agency for Academic Exchange (NAWA) [PN/BEK/2019/1/00421]; Ministry of Science and Higher Education (Poland)Ministry of Science and Higher Education, Poland [692/STYP/13/2018]; AGH Science and Technology, Poland [16.16.120.773]; Linkoping University (LiU) Center for Industrial Information Technology (CENIIT); LiU Cancer [VINNOVA/ITEA3 17021 IMPACT]; Swedish Foundation for Strategic ResearchSwedish Foundation for Strategic Research [RMX18-0056]; "la Caixa" FoundationLa Caixa Foundation [100010434]; European UnionEuropean Commission [847648, LCF/BQ/PI20/11760029]; Ministerio de Ciencia e Innovacion" of SpainSpanish Government [RTI2018-094569-B-I00]; National Institute for Biomedical Imaging [5R01EB027585-02]
